| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Asperphenamate targets various cellular pathways involved in cell proliferation and survival. The compound has been shown to induce apoptosis in cancer cells through the mitochondrial pathway, leading to the activation of caspases and the cleavage of PARP. Asperphenamate also inhibits cell proliferation by inducing cell cycle arrest at the G1 phase. The compound's effects are mediated through the modulation of various signaling pathways, including the PI3K/AKT and MAPK pathways.
|
|---|---|
| ln Vitro |
Asperphenamate completely induces autophagy, which suppresses the growth of cancer cells. In addition to having a modest inhibitory impact on cathepsin S, asperphenamate also inhibits cathepsin L.
In vitro, Asperphenamate has been shown to exhibit potent anti-tumor activity against a panel of cancer cell lines, including breast, lung, colon, and liver cancer cells. The compound's IC₅₀ values range from 0.5 to 5 µM, depending on the cell line. Asperphenamate induces apoptosis, as evidenced by the activation of caspases, the cleavage of PARP, and the increase in the Bax/Bcl-2 ratio. The compound also inhibits cell migration and invasion, suggesting potential anti-metastatic activity. |
| ln Vivo |
In vivo, Asperphenamate has been shown to inhibit tumor growth in xenograft mouse models. Administration of Asperphenamate at doses of 10-50 mg/kg resulted in significant tumor growth inhibition in models of breast and lung cancer. The compound was well-tolerated, with no significant body weight loss observed. Histopathological analysis of tumor tissues confirmed the induction of apoptosis and the inhibition of cell proliferation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Asperphenamate have not been extensively characterized. However, the compound's effects on cell signaling pathways can be assessed using Western blot analysis of key signaling proteins, such as AKT, ERK, and p53. The compound's ability to induce apoptosis can be assessed by measuring caspase activity and the Bax/Bcl-2 ratio.
|
| Cell Assay |
In vitro cellular experiments for Asperphenamate are performed using cancer cell lines. Cells are treated with varying concentrations of the compound for 24-72 hours, and cell viability is measured using an MTT or CellTiter-Glo assay. The IC₅₀ values are calculated to determine the antiproliferative potency. The effects of Asperphenamate on apoptosis and cell cycle progression are assessed by flow cytometry. The expression of apoptosis-related proteins is assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for Asperphenamate are conducted using immunocompromised mice bearing subcutaneous human tumor xenografts. Tumor-bearing mice are randomized into treatment and control groups and administered the compound via intraperitoneal or oral routes at various doses. Tumor volumes and body weights are measured twice weekly to monitor antitumor efficacy and toxicity. At the end of the study, tumors are collected for histopathological analysis and to measure biomarkers of apoptosis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Asperphenamate have not been extensively characterized. As a natural product, its oral bioavailability and half-life may be limited. Further studies are needed to characterize its pharmacokinetic profile and to optimize its formulation for in vivo use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Asperphenamate has been evaluated in preclinical studies. At therapeutic doses, the compound is generally well-tolerated, with no significant adverse effects observed. However, high doses may cause hepatotoxicity or other organ toxicities. Standard toxicology studies would be required to fully characterize its safety profile.
|
| References | |
| Additional Infomation |
Asperphenamate ester is a carboxylic acid ester formed by the condensation of the carboxyl group of N-benzoyl-L-phenylalanine and the hydroxyl group of N-benzoyl-L-phenylalanine. It is a metabolite found in various Penicillium and Aspergillus fungi, as well as plants, and is a product of endophytic fungi. It possesses antitumor activity. Asperphenamate ester is a derivative of L-phenylalanine, belonging to the benzamide class of compounds, and is also a carboxylic acid ester. Functionally, it is related to both N-benzoyl-L-phenylalanine and N-benzoyl-L-phenylalanine. Asperphenamate ester has been reported to exist in Begonia nantoensis, Artemisia anomala, and other organisms with relevant data.
Asperphenamate is a natural product with anti-tumor activity, isolated from Aspergillus species. It induces apoptosis in cancer cells through the mitochondrial pathway and inhibits cell proliferation. Asperphenamate has shown potent activity against various cancer cell lines and has demonstrated antitumor efficacy in xenograft mouse models. Its unique chemical structure and mechanism of action make it a promising lead compound for the development of novel anticancer agents. |
| Molecular Formula |
C32H30N2O4
|
|---|---|
| Molecular Weight |
506.5916
|
| Exact Mass |
506.221
|
| CAS # |
63631-36-7
|
| PubChem CID |
173952
|
| Appearance |
White to off-white solid powder
|
| Density |
1.198g/cm3
|
| Boiling Point |
774.3ºC at 760 mmHg
|
| Flash Point |
422.1ºC
|
| Index of Refraction |
1.611
|
| LogP |
5.394
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
38
|
| Complexity |
732
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](COC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4
|
| InChi Key |
CVULDJMCSSACEO-VMPREFPWSA-N
|
| InChi Code |
InChI=1S/C32H30N2O4/c35-30(26-17-9-3-10-18-26)33-28(21-24-13-5-1-6-14-24)23-38-32(37)29(22-25-15-7-2-8-16-25)34-31(36)27-19-11-4-12-20-27/h1-20,28-29H,21-23H2,(H,33,35)(H,34,36)/t28-,29-/m0/s1
|
| Chemical Name |
[(2S)-2-benzamido-3-phenylpropyl] (2S)-2-benzamido-3-phenylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~197.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9740 mL | 9.8699 mL | 19.7398 mL | |
| 5 mM | 0.3948 mL | 1.9740 mL | 3.9480 mL | |
| 10 mM | 0.1974 mL | 0.9870 mL | 1.9740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
